article thumbnail

Opinion: Breakthrough Therapies Act: Good idea, wrong solution

STAT

as a way to expand access for therapeutic purposes to potentially beneficial but highly regulated Schedule I substances like psilocybin and LSD, has the right underlying idea but provides a solution that is wrong. The Breakthrough Therapies Act , recently proposed by Senators Rand Paul (R-Ky.) and Cory Booker (D-N.J.)

article thumbnail

Eurofins BPT expands biopharma testing services in Canada

PharmaTech

With a focus on cGMP compliance, the facility provides chemistry, microbiology, and regulatory consulting services, including testing for controlled substances. It ensures consistent quality across its network, prioritizing customer satisfaction and regulatory compliance throughout the drug development process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA publishes recommendations on psychedelic clinical trial design

European Pharmaceutical Review

Dr Tiffany Farchione, Director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research stated the regulatory body “hopes to outline the challenges inherent in designing psychedelic drug development programmes” and provide potential solutions.

article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Most psychedelic drugs are Schedule I controlled substances, which means that very strict legal and regulatory controls accompany their use” Some psychedelics originate in nature and have been used by Indigenous cultures for thousands of years; others are manipulated or manufactured. Fast track designation.

article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

However, at the federal level, cannabinoids remain illegal under the Controlled Substances Act. These countries utilize full legal oversight on cannabinoid medical use, cultivation and trade, which has established a robust regulated market, helping the region to deal with future developments.

article thumbnail

Hyman, Phelps & McNamara, P.C. Takes Top Honors in Two Prestigious Categories in 2023 LMG Life Sciences Awards

FDA Law Blog: Biosimilars

The LMG awards are reflective of HPM’s excellence across several of our core life sciences practices, from controlled substances work to drug development, to Hatch-Waxman, to drug pricing, to medical device regulation. is the largest dedicated food and drug law firm in the country.

article thumbnail

Five Trends in Contract Drug Manufacturing Organisations

Pharmaceutical Technology

The company focuses on small molecule, oral liquid, and solid dose products, providing formula development, method development, cleaning verification methods, tech transfer, pilot studies, commercial scale-up, and packaging. This will help determine if there are any special handling requirements.